CurrentArizona Complete HealthPolicy CP.MP.181

Polymerase Chain Reaction Respiratory Viral Panel Testing

Medical necessity criteria and coding guidance for multiplex respiratory PCR (respiratory viral panel) testing for non-Medicare plans affiliated with Centene Corporation; defines when panels of varying sizes are considered medically necessary and lists supporting CPT and ICD-10 codes.

Policy Summary

PayerArizona Complete Health

PolicyPolymerase Chain Reaction Respiratory Viral Panel Testing

Policy CodePolicy CP.MP.181

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDocument specific clinical indication, reason for panel testing, provider type/specialty and place of service in the medical record before ordering.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

876313-5 targets

876326-11 targets

8763312-25 targets

Multiple ICD-10Diagnosis lists

Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Section I - 1: Member has an appropriate clinical indication for infectious disease testing: either immunocompetent with presumption of active infection or infection-associated complications requiring identification of a causative organism for appropriate management, OR immunocompromised (including HIV/AIDS, those on immunosuppressive medications such as chemotherapy, biologics, transplant immunosuppressants, high‑dose systemic corticosteroids, or inherited immunodeficiency). In immunocompromised persons testing may be performed once as part of a pre‑transplant evaluation regardless of symptoms.

From I.A.1-2

Section I - 2: Results of testing will impact clinical management in a manner already demonstrated in the peer‑reviewed published literature to improve outcomes.

From I.B

Section I - 3: Testing is performed according to the intended use of the test and in the intended population for which the test was developed and validated.

From I.C

Section I - 4: Targeted testing is not appropriate (i.e., targeted testing will not provide sufficient information for appropriate clinical management).

From I.D

Section I - 5: The panel performed includes at least the minimum pathogen targets required for clinical decision making for its intended use that can be reasonably detected by the test.

From I.E

Section I - 6: The registered test demonstrates equivalent or superior analytical and clinical validity to established standard‑of‑care methods (e.g., culture, pathogen‑specific PCR) for the majority of targets included on the panel.

From I.F

Section I - 7: Medical record documents specific clinical indications for testing, specific reasons for performing panel testing, and provider type/specialty and place of service.

From I.G

Criteria for panels with 6 or more targets

RVPs with six pathogens or more are considered medically necessary when the Section I criteria are met AND any ONE of the following:

Section II - A: Performed in a healthcare setting that cares for critically ill individuals (e.g., emergency department, inpatient hospital, or observation status).

II.A.1

Section II - B: Member is immunocompromised as defined in Section I.A.2.

II.A.2

Section II - C: Member is immunocompetent AND both: (a) has severe and established underlying respiratory pathology (e.g., severe asthma, COPD, cystic fibrosis, pulmonary fibrosis, prior lung radiation) AND (b) treatment with antibiotics may be indicated according to established guidelines.

II.A.3.a-b

Panel-specific medical necessity (summary)

Policy includes distinct medical necessity statements for panels of five pathogens or fewer and panels of six or more; criteria and code/linkage requirements have been adjusted over time.

Panel size based rules: Separate medical necessity criteria exist for panels of ≤5 targets versus ≥6 targets. Revision history documents splitting the statements, addition/removal of specific CPT/PLA codes, movement of codes (e.g., 87632/87633) to POS‑linked medically necessary tables, and addition of codes (e.g., 0202U, 0223U, 0225U) to CPT tables. Outpatient criteria for ≤5‑target panels were refined to require that the test will influence plan of care and included specific indications (e.g., immunocompromised, when rapid COVID‑19 testing not available to influence care, or when ordered by an Infectious Disease specialist). Providers should refer to current Table(s) for CPT/POS/ICD‑10 linkage requirements.

Summary of revision history and panel distinctions

When selecting testing for suspected respiratory infection, the policy emphasizes preference for targeted testing whenever it will provide sufficient diagnostic information for clinical management. Panel testing is appropriate only when targeted testing is not appropriate (will not provide sufficient information for the appropriate clinical management) and when the other panel-specific criteria are met (see Section I requirements for panels of five pathogens or fewer and additional rules for larger panels).

Providers must ensure the panel chosen aligns with the intended use and validated population for the registered test and that the panel includes at least the minimum pathogens required for clinical decision making; if a focused, pathogen-specific test would answer the clinical question, the more limited targeted test should be used instead of a multi-pathogen panel.

The policy notes that the diagnostic value of multi-pathogen respiratory viral panels is limited when identification of a pathogen will not alter clinical management. Although PCR panels are highly sensitive and specific and can inform antiviral use, infection control, and reduce unnecessary antibiotic prescribing, identification of a specific virus often does not change individual patient care; therefore panels should not be used when results are unlikely to influence treatment or disposition.

inv-25: Diagnosis of respiratory viral infection in patients meeting clinical criteria — covered indications

Covered populationsImmunocompetent patients with suspected active infection or infection-related complications; immunocompromised patients; critically ill patients (ED, inpatient, observation); patients with severe underlying respiratory disease where antibiotics may be indicated.

Immunocompromised noteIncludes persons with HIV/AIDS, on immunosuppressive medications (chemotherapy, biologics, transplant-related immunosuppressants, high‑dose systemic corticosteroids), or with inherited immune deficiencies; atypical presentations are appropriate indications.

Clinical impact requirementResults must be expected to impact clinical management in ways demonstrated in peer‑reviewed literature to improve outcomes.

Testing contextPanels are medically necessary only when targeted testing is not appropriate (will not provide sufficient information for management).

Test performance and intended useTesting must be performed according to the intended use/validated population and the registered test must demonstrate equivalent or superior analytical and clinical validity to standard methods for most targets.

Immunocompromised status and related diagnoses support medical necessity

The policy lists many immunocompromising diagnoses and transplant/therapy statuses that support medical necessity for respiratory viral PCR panels (see ICD‑10 list additions in revision history).

Immunocompromised diagnoses support: Member has one or more diagnoses listed in the ICD‑10 tables supporting medical necessity (examples include HIV disease, aplastic anemia and related bone marrow failure syndromes, congenital and acquired immunodeficiencies, neutropenia, antibody deficiencies, severe combined immunodeficiency, immunodeficiency due to drugs, graft‑versus‑host disease, history/status of organ or stem cell transplant, and encounters for antineoplastic chemotherapy or cellular therapies). Many codes were added to Table 5 across revisions to explicitly support medical necessity for immunocompromised and transplant populations.

See Table 5 additions in revision history

Transplant and pre‑transplant status: Member has documented transplant status (e.g., Z94.* codes) or is undergoing pre‑transplant evaluation; testing may be performed once as part of pre‑transplant evaluation in immunocompromised persons regardless of symptoms.

Pre‑transplant allowance from I.A.2 and revision notes

Provider Responsibilities & Billing Alerts

Billing Rule

Code & POS linkage required

Code and place-of-service (POS) linkage is required for medical necessity determinations for certain respiratory viral panel CPT/PLA codes. Verify that the CPT/PLA code billed is supported by an allowed POS (see Table 3) and by an appropriate ICD-10 diagnosis per the policy tables; tests billed without the required CPT+POS and diagnosis combinations may not meet medical necessity.

Ensure billed CPT/PLA code is paired with an approved Place of Service from Table 3 when required.
When Table 2 or Table 4 require specific diagnosis codes, include an applicable ICD-10 on the claim.
Codes 0098U, 0099U, 0100U, 0115U and other listed CPTs are subject to POS/diagnosis linkage per revision history; verify current table assignments.

Denial Risk

Denial risk for unmet criteria or missing documentation

Tests that do not meet the policy medical necessity criteria (sections I and II) or for which required documentation is missing are subject to denial. Common denial triggers include lack of clinical indication, failure to show why targeted testing was insufficient, and absence of required POS/diagnosis linkage when applicable.

Claims lacking documentation that the test result would impact clinical management as required by I.B may be denied.
Panels ordered when targeted testing would have been sufficient (per I.D) risk denial.
Billing CPT codes without the corresponding POS or approved ICD-10 diagnosis listed in Tables 3–5 may be denied.

Documentation Required

Documentation required in the medical record

Required documentation must be present in the medical record to support medical necessity. Maintain clear documentation of clinical indications, rationale for panel testing, and billing context (provider type and place of service).

Document specific clinical indications/suspicion for the pathogen (I.G.1).
Document specific reasons why a panel (rather than targeted testing) is being performed (I.G.2 and I.D).
Document provider type/specialty and Place of Service (I.G.3).
Retain records showing how test results would influence clinical management (I.B).

Prior Authorization

Preference for targeted testing

Use targeted testing when it will provide sufficient information for appropriate clinical management. Panel testing (multiple-pathogen panels) should be used only when targeted testing is not appropriate or insufficient, and when the panel includes the minimum pathogens required for clinical decision making.

If targeted testing can identify the likely pathogen and guide treatment, order targeted tests instead of panels.
When ordering a panel, document why targeted testing was insufficient and confirm the panel meets test performance and pathogen inclusion requirements (I.E, I.F).

Note

Provider note — follow policy revisions for code/diagnosis/POS linkage

Policy revisions have clarified and added requirements tying CPT/PLA codes to specific diagnosis and place-of-service codes; providers should bill with the appropriate combinations and consult the most recent tables and revision notes when submitting claims.

Refer to the latest revision dates (see policy history) for changes to Table 2, Table 3, and ICD-10 code lists.
Billing practices changed over time (codes moved/added/deleted); verify current policy tables before claim submission.

How to Order & Documentation Expectations

Documentation Required

Orderers must record indication, panel rationale, provider type and POS; larger panels need extra linkages

When ordering, document the clinical indication, the specific reason for choosing panel testing over targeted testing, and the provider type/specialty and place of service; larger panels (Table 2 codes) additionally require the POS or paired diagnosis codes specified in Tables 3–5.

For panels of six or more targets, ensure the order includes the care setting (ED, inpatient, observation) or the qualifying diagnosis/clinical circumstance described in Section II.
Attach supporting clinical notes to the laboratory order when possible.

Documentation Required

Outpatient ≤5-target panels require documented indication when ordered by/without an ID specialist

For outpatient orders of panels with five or fewer targets, include the clinical indication when the test is ordered by an Infectious Disease specialist or when an ID specialist is not available; this supports the outpatient medical necessity criteria added in revisions.

Document if the order was placed by an ID specialist or if ID consult was not available and why outpatient panel testing is still needed.

Exclusions and Limitations

Panels performed when the identification of a pathogen will not influence clinical management are not supported. If a targeted test (one or a small number of analytes) would provide the necessary information for decision-making, the targeted approach is preferred and panel testing is not covered.

For panels of five pathogens or fewer, the policy requires that targeted testing be inappropriate and that test results will impact clinical management and meet the other Section I requirements; panels done solely for broad surveillance or when results will not change patient care do not meet medical necessity.

The policy revision history documents removal of COVID-19–specific criteria in Section I.A (noted in the 08/21 revision). In the current policy window there are no standalone COVID-19 exclusions or criteria retained — COVID-19–specific language referenced in earlier versions has been deleted.

Key Terms

inv-22: RVP definition

DefinitionMultiplex PCR respiratory viral panel (RVP): a single test detecting RNA or DNA of multiple respiratory viruses, often performed from nasal, nasopharyngeal, or oropharyngeal swabs.

Typical pathogens detectedMay include rhinovirus, parainfluenza, coronavirus, adenovirus, respiratory syncytial virus (RSV), human metapneumovirus, influenza, Coxsackie virus (varies by panel).

Clinical roleUsed to identify viral etiologies to inform antiviral use, infection control, and potentially reduce unnecessary antibiotics, though identification may not always change individual management.

inv-23: Immunocompromised

DefinitionImmunocompromised: individuals with weakened immune systems including those with HIV/AIDS, those taking immunosuppressive medications (chemotherapy, biologics, transplant immunosuppressants, high‑dose systemic corticosteroids), and those with inherited immune deficiencies.

Examples - HIV/AIDSPersons with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).

Examples - Immunosuppressive therapyPatients receiving chemotherapy, biologic agents, transplant-related immunosuppressive drugs, or high‑dose systemic corticosteroids.

Examples - Inherited deficienciesCongenital immunoglobulin deficiencies and other inherited immune system disorders.

inv-24: Panel size distinction

Panel size categoriesPolicy distinguishes panels of five pathogens or fewer versus panels of six or more with separate medical necessity statements.

<=5 pathogen panelsConsidered medically necessary when Section I criteria (detailed clinical indications, impact on management, test validity, and documentation) are met.

>=6 pathogen panelsRequire Section I criteria plus at least one additional condition: performed in critically ill setting, patient is immunocompromised, or immunocompetent with severe underlying respiratory disease and possible antibiotic treatment per guidelines.

Testing Frequency Constraints

inv-27: Pre-transplant testing allowance

Pre-transplant allowanceIn immunocompromised individuals, respiratory viral panel testing may be performed once as part of pre‑transplant evaluation regardless of symptoms.

DocumentationMedical record must document clinical indications and reason for testing even for pre‑transplant evaluation to support medical necessity.

PopulationApplies to immunocompromised patients as defined in policy (HIV/AIDS, immunosuppressive therapy, inherited immune deficiencies).

inv-28: Frequency limits / revision-linked notes

Frequency limits summaryPolicy includes frequency limits section; pre‑transplant single test allowance is specified for immunocompromised patients. (Other frequency items referenced in revision history and tables.)

Revision-linked placeholderPolicy revision history documents additions and removals of CPT/PLA codes and updates to tables; providers should reference current tables for exact frequency or billing constraints.

Billing linkage reminderTests must be billed with matching CPT/POS and supporting ICD‑10 codes per Tables 2–5 to avoid denial; frequency rules may be enforced in claims review.

Clinical Background

Multiplex PCR respiratory viral panels (RVPs) detect nucleic acid (RNA or DNA) from multiple respiratory viruses, typically from nasal, nasopharyngeal, or oropharyngeal swabs. These assays can identify common viral causes of respiratory illness (for example, rhinovirus, parainfluenza, adenovirus, respiratory syncytial virus, human metapneumovirus, and influenza) and are generally highly sensitive and specific.

While PCR RVPs can assist with antiviral decisions, infection control, and reducing unnecessary antibiotic use—especially in immunocompromised or critically ill patients—routine identification of a specific virus does not always change individual patient management, so use should be guided by the clinical context and the policy’s medical necessity criteria.

Policy Revision Timeline

12/19policy_development

Policy developed (approval date 01/20) and initial content added including note to refer to CP.MP.183 for 2019‑novel coronavirus testing.

03/20revision

Policy split medical necessity statements to address panels of 5 or fewer versus 6 or more targets; added outpatient criteria for ≤5‑target panels and moved CPT codes 87632 and 87633 to a medically necessary table when billed with specific POS; added PLA codes 0098U, 0099U, 0100U, and 0115U as medically necessary when billed with POS codes in Table 3.

08/20revision

References reviewed and updated; reaffirmed split of medical necessity statements and outpatient indications for ≤5‑target panels; codes 87632/87633 retained in POS‑linked medically necessary table and PLA codes 0098U–0100U and 0115U listed as medically necessary when billed with POS in Table 3.

04/21code_updateLatest

CPT/PLA codes 0098U, 0099U, and 0100U were deleted (removed) from the code set.

Policy Summary

PayerArizona Complete Health

PolicyPolymerase Chain Reaction Respiratory Viral Panel Testing

Policy CodePolicy CP.MP.181

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDocument specific clinical indication, reason for panel testing, provider type/specialty and place of service in the medical record before ordering.

SourceLink

On This Page

OpenPayer

Polymerase Chain Reaction Respiratory Viral Panel Testing

Medical Necessity Criteria

Billing and Code Lists

Provider Responsibilities & Billing Alerts

How to Order & Documentation Expectations

Exclusions and Limitations

Key Terms

Testing Frequency Constraints

Clinical Background

Policy Revision Timeline